ENG/中
老虎证券
行情
交易
收费
下载
优惠与活动
帮助
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
股权激励
关于
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
GSK plc ADRhedged
76.05
-0.0459
-0.06%
成交量:
489.00
成交额:
3.72万
市值:
76.05万
市盈率:
- -
高:
76.05
开:
75.91
低:
75.91
收:
76.09
52周最高:
85.03
52周最低:
48.14
股本:
1.00万
流通股本:
1.00万
量比:
2.19
换手率:
4.89%
股息:
0.79
股息率:
1.04%
净资产收益率:
--
总资产收益率:
--
市净率:
--
市盈率(LYR):
- -
数据加载中...
总览
公司
新闻资讯
公告
跨国药企2025年成绩单:“药王”易主,创新资产交易创新高
21世纪经济报道
·
03/10
跨国药企濒临3000亿美元专利悬崖
国际金融报
·
02/28
GSK收购35Pharma 获得肺动脉高压新药;全球首款血友病基因疗法退市 | 医药早参
每日经济新闻
·
02/26
葛兰素史克将以9.5亿美元收购生物技术公司35Pharma
格隆汇
·
02/25
葛兰素史克(GSK.US)9.5亿美元收购35 Pharma,发力心血管药物赛道
智通财经
·
02/25
超10亿美元!前沿生物牵手GSK 小核酸赛道再升温
21世纪经济报道
·
02/24
股海导航_2026年2月24日_沪深股市公告与交易提示
股市直击
·
02/24
四大证券报头版头条内容精华摘要_2026年2月24日_财经新闻
股市直击
·
02/24
和铂医药宣布新一代CTLA-4抗体授权交易;前沿生物与葛兰素史克签署授权许可协议 | 医药早参
每日经济新闻
·
02/24
前沿生物(688221.SH)与葛兰素史克签署授权许可协议
智通财经
·
02/23
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠:港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投,免费实时行情与多种工具,立即开户享更多优惠!","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠:港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投,免费实时行情与多种工具,立即开户享更多优惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/GSKH/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":76.0458,"timestamp":1773691200000,"preClose":76.09168,"halted":0,"volume":489,"delay":0,"changeRate":-0.000602956854152738,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"已收盘","change":-0.04588,"latestTime":"03-16 16:00:00 EDT","open":75.91,"high":76.0458,"low":75.91,"amount":37150.4265,"amplitude":0.001785,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1773734400000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":76.09168,"nav":76.884151,"aum":768918.394151,"dividendRate":0.010356,"bidAskSpread":0,"volumeRatio":2.186942},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.186942,"shares":10001,"dividePrice":0.7875,"high":76.0458,"amplitude":0.001785,"preClose":76.09168,"low":75.91,"week52Low":48.14,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":76.0458,"eps":0,"divideRate":0.010356,"volume":489,"delay":0,"ttmEps":0,"open":75.91,"prevYearClose":68.2031,"prevWeekClose":76.455,"prevMonthClose":82.5898,"prevQuarterClose":68.2031,"fiveDayClose":78.0867,"twentyDayClose":80.7182,"sixtyDayClose":68.2433},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618933958","title":"跨国药企2025年成绩单:“药王”易主,创新资产交易创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618933958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618933958?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 17:04","pubTimestamp":1773133472,"startTime":"0","endTime":"0","summary":"随着跨国药企陆续披露2025年业绩报告,全球制药行业的新一轮竞争格局逐步清晰。业绩榜单中,强生以全球941.93亿美元的总营收斩获榜首,旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元(+6%)和337.92亿美元(+6.1%);礼来凭借44%的高增速,实现651.79亿美元的全年营收,成为增速最快的头部药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667509930.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667509930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","LU1934455863.HKD","LU1093756325.SGD","CDE","LU2361045086.USD","SG9999015358.SGD","IE00BJJMRZ35.SGD","LU2360032135.SGD","GSKH","MRK","BK4588","LU0477156953.USD","SGXZ57979304.SGD","BK4534","LU1983299246.USD","NVOX","LU0130517989.USD","LU0648001328.SGD","LU2125154778.USD","LU2324357040.USD","GSK.UK","IE00B1BXHZ80.USD","LU0320765489.SGD","LU1066051811.HKD","LU0203347892.USD","LU0868494617.USD","IE00BKVL7J92.USD","LU1223082519.USD","LU1989772840.SGD","BK4559","BK4550","BK4585","LU1023059063.AUD","LU2361044865.SGD","LU1291159041.SGD","SG9999014575.USD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","LU1571399168.USD","LU0289739699.SGD","BK4516","LU0098860793.USD","GSK","LU1066051225.USD","LU0266013472.USD","SG9999001176.USD","SG9999014542.SGD","01477","LU1057294990.SGD","NVOH"],"gpt_icon":1},{"id":"2614889372","title":"跨国药企濒临3000亿美元专利悬崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2614889372","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614889372?lang=zh_cn&edition=fundamental","pubTime":"2026-02-28 07:50","pubTimestamp":1772236210,"startTime":"0","endTime":"0","summary":"近期,强生、罗氏、礼来等多家跨国药企相继披露2025年业绩。其中,强生以942亿美元总营收位居首位,罗氏凭借五大重磅药物获得744.3亿美元收入,位居第二;得益于替尔泊肽双靶点减肥药,礼来以651.79亿美元挤进前三,成为2025年业绩榜最大黑马。总体看,大部分跨国药企业绩实现了稳定增长,部分明星药品对业绩影响较大。业内人士认为,专利悬崖冲击将是巨头们接下来要面临的核心压力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602283657287047.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602283657287047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2125154935.USD","LU1496350502.SGD","LU1196500208.SGD","LU1244550577.SGD","SG9999013999.USD","LU0203347892.USD","LU2750360997.AUD","LU0985320562.USD","IE0034235303.USD","PFE","LU0345769128.USD","LU1674673428.USD","LU2602419157.SGD","IE00BVYPNW00.USD","LU0980610538.SGD","IE00B7SZLL34.SGD","LU1989772840.SGD","LU0321505439.SGD","LU2023250504.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1093756168.USD","LU2750360641.GBP","LU1244550221.USD","LU1935042991.SGD","LU1032466523.USD","BK4516","LU0289739699.SGD","LU0203345920.USD","LU1989771016.USD","LU1280957306.USD","LU2112291526.USD","LU2471134952.CNY","SG9999003800.SGD","IE00B19Z3581.USD","LU1074936037.SGD","LU0320765646.SGD","LU2125154778.USD","LU0208291251.USD","LU1069347547.HKD","LU1267930813.SGD","IE0009355771.USD","BK4187","LU0795875086.SGD","LU0106261372.USD","IE000M9KFDE8.USD","LU1037948541.HKD","SG9999002224.SGD","BK4533","LU0265550946.USD","IE00BDGV0183.EUR","IE00BVYPNV92.GBP","LU1023059063.AUD","IE00BJT1NW94.SGD","LU0130102774.USD","BK4588","BK4599","LU0912757837.SGD","LU0238689110.USD","IE00BBT3K403.USD","LU0985481810.HKD","LU2461242641.AUD","BK4585","LU0965508806.USD","SG9999014559.SGD","IE00B1BXHZ80.USD","LU1093756325.SGD","LU1894683264.USD","LU0456855351.SGD","LU0477156953.USD","LU0965509101.SGD","LU1057294990.SGD","LU2471134796.USD","LU2023250843.SGD","LU0306806265.USD","LLY","LU1162221912.USD","IE00BGHQF631.EUR","LU0124676726.USD","LU1917777945.USD","IE0002270589.USD","LU1066051498.USD","SG9999015358.SGD","LU1059921491.USD","LU2089984988.USD","SG9999015341.SGD","IE00B3PB1722.GBP","LU1941712264.USD","LU1829250122.USD","LU1201861249.SGD","IE0001KFT4U8.USD","LU1934455863.HKD","LU2133065610.SGD","LU2505996509.AUD","IE0002141913.USD","LU2324357040.USD","LU2129689605.HKD","GSKH","LU0861579265.USD","LU2471134879.HKD","LU2106854487.HKD","LU0070217475.USD","IE00BLSP4452.SGD","LU0225771236.USD","LU1732800096.USD","LU1929549753.HKD","SG9999001440.SGD","SG9999014567.USD","LU0006306889.USD","LU2430703095.HKD","IE00BLSP4239.USD","BK4077","LU0466842654.USD","IE00BN8TJ469.HKD","LU1699723380.USD","LU1037948897.HKD","LU0792757196.USD","LU1221951129.SGD","IE00B19Z3B42.SGD","LU2430703251.USD","LU0130517989.USD","BK4504","NVO","LU2361045086.USD","LU1066053197.SGD","LU1291159041.SGD","LU2129689431.USD","LU1506573853.SGD","LU1116320737.USD","BK4532","LU0321505868.SGD","LU1718418525.SGD","LU2592432038.USD","LU0234572021.USD","SG9999011175.SGD","LU0965509010.AUD","LU1244550494.USD","LU0320765489.SGD","LU0965509283.SGD","LU1061106388.HKD","LU1989772923.USD","LU0170899867.USD","LU2129689514.USD","LU0211331839.USD","LU2430703178.SGD","LU2505996681.GBP","BK4568","LU0787776722.HKD","SG9999002232.USD","IE00BJJMRZ35.SGD","IE00BKVL7J92.USD","LU0345770993.USD","LU1974910355.USD","SG9999001176.USD","LU0868494617.USD","LU2347655156.SGD","SGXZ57979304.SGD","LU1066051225.USD","BK4581","LU0648001328.SGD","IE00BFXG1179.USD","LU0070302665.USD","LU0114720955.EUR","SG9999001176.SGD","LU1983299246.USD","GSK.UK","LU0432979614.USD","LU1883839398.USD","LU1934455194.USD","LU0098860793.USD","LU0225284248.USD","LU1430594728.SGD","BK4592","LU0345770308.USD","LU2361044865.SGD","LU1674673691.USD","GSK","IE00B3T34201.USD","LU0265550359.USD","LU0683600562.USD","JNJ","LU1778281490.HKD","SNY","LU0640476718.USD","BK4559","LU0234570918.USD","LU0795875169.SGD","NVS","LU1934455277.USD","BK4534","LU1732799900.SGD","IE00B42XCP33.USD","LU1571399168.USD","BK4007","LU0122379950.USD","LU0882574055.USD","LU0266013472.USD","MRK","IE00BZ1G4Q59.USD","LU1585245621.USD","LU2360032135.SGD","AZN","LU1032955483.USD","LU1894683348.USD","RHHBY","IE00BSNM7G36.USD","LU0306807586.USD","IE00BFTCPJ56.SGD","LU2361044949.HKD","LU1914381329.SGD","LU2468319806.SGD","LU1116320901.HKD","LU1941712348.USD","SG9999014542.SGD","BK4550","SG9999014575.USD","LU0058720904.USD","LU0345769631.USD","LU0689626769.HKD","LU0889566641.SGD","LU1261432733.SGD","LU1035773651.USD","LU2471134523.USD","LU1221951046.USD","LU1066051811.HKD"],"gpt_icon":1},{"id":"2614450050","title":"GSK收购35Pharma 获得肺动脉高压新药;全球首款血友病基因疗法退市 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2614450050","media":"每日经济新闻","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614450050?lang=zh_cn&edition=fundamental","pubTime":"2026-02-26 07:06","pubTimestamp":1772060804,"startTime":"0","endTime":"0","summary":"丨2026年2月26日星期四丨NO.1先声药业2025年归母净利润预增80.1%至93.9%2月25日,先声药业发布盈利预告,公司2025财政年度将录得收入约人民币77亿元至78亿元,同比增长约16.0%至17.6%;将录得归属于本公司权益股东的利润约人民币13亿元至14亿元,同比增长约80.1%至93.9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602263654473544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263654473544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4532","GSK","BK1161","BK4585","BK4588","159938","GSKH","BK1515","09939","LU1829250122.USD","BK1574","GSK.UK"],"gpt_icon":0},{"id":"2614217087","title":"葛兰素史克将以9.5亿美元收购生物技术公司35Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2614217087","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614217087?lang=zh_cn&edition=fundamental","pubTime":"2026-02-25 21:28","pubTimestamp":1772026083,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","LU1829250122.USD","BK4007","GSK.UK","BK4585","GSK","BK4588","GSKH"],"gpt_icon":0},{"id":"2614701423","title":"葛兰素史克(GSK.US)9.5亿美元收购35 Pharma,发力心血管药物赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2614701423","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614701423?lang=zh_cn&edition=fundamental","pubTime":"2026-02-25 16:45","pubTimestamp":1772009150,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,葛兰素史克已同意收购 35Pharma Inc.,这是一家拥有早期高血压药物资产的生物技术公司。此举标志着这家英国制药巨头正向心血管药物领域扩张。葛兰素史克在周三的一份声明中表示,将以 9.5 亿美元现金收购这家私人持有的加拿大公司。葛兰素史克目前最大的财务压力来自于其支柱性 HIV 药物将在 2028 年前后遭遇专利到期。1月20日,葛兰素史克还宣布收购美国上市药企RAPT Therapeutics。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克(GSK.US)9.5亿美元收购35 Pharma,发力心血管药物赛道","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","GSK","GSKH","LU1829250122.USD","BK4585","BK4588","GSK.UK","BK4007"],"gpt_icon":0},{"id":"2613764331","title":"超10亿美元!前沿生物牵手GSK 小核酸赛道再升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2613764331","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613764331?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 14:08","pubTimestamp":1771913295,"startTime":"0","endTime":"0","summary":"小核酸领域再迎重磅BD(商务拓展)交易。2月23日晚间,科创板创新药企前沿生物(688221.SH)公告,已与葛兰素史克(GSK)达成一项独家授权许可协议,GSK获得公司两款小核酸(siRNA)管线产品在全球范围内的独家开发、生产及商业化权利。协议显示,其中一款候选药物已进入新药临床试验申请(IND)阶段,另一款为临床前候选药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652625697.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652625697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","LU1829250122.USD","688221","GSK","GSKH","BK4532","BK0239","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"2613975138","title":"股海导航_2026年2月24日_沪深股市公告与交易提示","url":"https://stock-news.laohu8.com/highlight/detail?id=2613975138","media":"股市直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613975138?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 08:30","pubTimestamp":1771893000,"startTime":"0","endTime":"0","summary":"经初步测算,预计本次方案将对公司2026年度归母净利润产生一定负面影响,影响金额低于公司2024年度经审计归母净利润的5%,不会对公司整体业务发展产生实质性影响。 ST京蓝公告,自2026年1月23日至2026年2月13日期间公司股票价格涨幅为86.90%,短期内价格涨幅较大,公司业绩未发生重大变化,但近期公司股票价格严重脱离公司业绩情况,投资者参与交易可能面临较大风险,如未来公司股票价格进一步异常上涨,公司可能申请停牌核查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-02-24/doc-inhnwmhy3272551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","GSK.UK","LU1829250122.USD","IND","GSK","BK4532","BK4007","BK4585","GSKH"],"gpt_icon":0},{"id":"2613751897","title":"四大证券报头版头条内容精华摘要_2026年2月24日_财经新闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2613751897","media":"股市直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613751897?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 08:29","pubTimestamp":1771892940,"startTime":"0","endTime":"0","summary":" 2月24日(星期二),今日报刊头条主要内容精华如下:。中方敦促美方取消对贸易伙伴加征的有关单边关税措施。 2月23日晚,国投瑞银基金发布公告称,近期国投白银LOF二级市场交易价格出现较大幅度溢价。 截至2月23日18时,2026年春节档电影总票房已突破56亿元,总场次刷新中国影史春节档最高纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/y/2026-02-24/doc-inhnwmhw6169991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4532","BK4007","GSKH","GSK.UK","SImain","BK4588","BK4585","LU1829250122.USD","GSK"],"gpt_icon":0},{"id":"2613133755","title":"和铂医药宣布新一代CTLA-4抗体授权交易;前沿生物与葛兰素史克签署授权许可协议 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2613133755","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613133755?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 07:02","pubTimestamp":1771887756,"startTime":"0","endTime":"0","summary":"丨2026年2月24日星期二丨NO.1和铂医药就新一代CTLA-4抗体达成授权协议及股权合作2月23日,和铂医药公告称,公司与SOLSTICEONCOLOGY就HBM4003订立授权协议及股权合作协议。据此,公司同意向SolsticeOncology授予独家授权,以在大中华区以外地区开发及商业化其临床阶段组合资产HBM4003。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652107028.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652107028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK4007","BK4585","GSKH","BK1161","BK4532","BK1574","BK0239","BK1583","LU1829250122.USD","GSK","02142","BK4588","159938","688221","09939","GSK.UK"],"gpt_icon":0},{"id":"2613788810","title":"前沿生物(688221.SH)与葛兰素史克签署授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2613788810","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613788810?lang=zh_cn&edition=fundamental","pubTime":"2026-02-23 16:57","pubTimestamp":1771837051,"startTime":"0","endTime":"0","summary":"智通财经APP讯,前沿生物 发布公告,公司与全球生物制药企业葛兰素史克达成一项独家授权许可协议。葛兰素史克将负责两款产品之后所有的全球临床开发、监管申报及商业化活动。本次与全球领先的生物制药企业GSK达成此项协议,体现了公司在小核酸药物研发领域的技术实力与平台价值正获得国际市场认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688221","BK0239","BK4532","BK4585","BK4588","BK4007","GSK.UK","LU1829250122.USD","GSK","GSKH"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}